Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Toremifene Citrate: Molecular Insights and Next-Gen Strat...
2026-03-04
Explore the advanced molecular pharmacology and translational applications of Toremifene Citrate, a leading oral selective estrogen receptor modulator for cancer research. This in-depth guide reveals unique mechanistic insights and new research paradigms for estrogen receptor signaling.
Optimizing Opioid Receptor Assays with nor-Binaltorphimin...
2026-03-03
This evidence-based guide addresses key experimental challenges in opioid receptor pharmacology and pain modulation research, focusing on nor-Binaltorphimine dihydrochloride (SKU B6269). Using real-world scenarios, it demonstrates how APExBIO’s high-purity, selective κ-opioid receptor antagonist enhances reproducibility and data confidence in cell viability and signal transduction workflows.
Erastin: Charting the Future of Ferroptosis—Mechanistic M...
2026-03-03
This thought-leadership article explores the mechanistic underpinnings and translational promise of Erastin, a pioneering ferroptosis inducer, for cancer researchers. Integrating the latest mechanistic insights—including the potentiating effects of BRD4 inhibition—and strategic guidance for experimental and clinical workflows, this piece advances beyond conventional product literature to deliver actionable intelligence for the next wave of ferroptosis-focused oncology research.
AG-490 (Tyrphostin B42): Reliable JAK2/STAT Inhibition fo...
2026-03-02
This scenario-driven article explores how AG-490 (Tyrphostin B42), SKU A4139, addresses real laboratory challenges in cancer and immunopathology research. With evidence-based Q&A, it demonstrates the reagent’s reliability, purity, and mechanistic specificity for JAK2, EGFR, and STAT pathway inhibition. Learn best practices for experimental design, data interpretation, and product selection through the lens of AG-490’s validated performance.
Afatinib in Patient-Derived Assembloids: Redefining EGFR/...
2026-03-02
Explore how Afatinib, an irreversible ErbB family tyrosine kinase inhibitor, empowers advanced cancer biology research using patient-derived assembloid models. This article uncovers unique insights into tumor–stroma interactions and drug resistance, offering a distinct application focus beyond conventional workflows.
BMS 599626 Dihydrochloride: Precision EGFR/ErbB2 Inhibiti...
2026-03-01
BMS 599626 dihydrochloride is a highly selective EGFR and ErbB2 inhibitor that empowers researchers to dissect oncogenic signaling and senescence pathways with nanomolar potency. Its robust inhibition of HER tyrosine kinases and ability to disrupt HER1/HER2 heterodimerization make it indispensable for advanced breast and lung cancer models. APExBIO supplies this validated tool for reproducible workflows and translational insight.
Erastin as a Transformative Ferroptosis Inducer in Advanc...
2026-02-28
Explore how Erastin, a potent ferroptosis inducer, offers new frontiers in cancer biology research by targeting iron-dependent, non-apoptotic cell death in RAS/BRAF-mutant tumors. This comprehensive article reveals advanced mechanistic insights and unique translational applications not covered elsewhere.
Gefitinib (ZD1839): Redefining EGFR Inhibition in Complex...
2026-02-27
Discover how Gefitinib (ZD1839), a selective EGFR tyrosine kinase inhibitor, advances cancer research by enabling precise EGFR signaling pathway inhibition and apoptosis induction in physiologically relevant assembloid models. This article uniquely explores the integration of stromal components and personalized therapy strategies.
Prochlorperazine: Mechanistic Insights and Frontier Oncol...
2026-02-27
Explore the multifaceted role of Prochlorperazine as a dopamine D2 receptor antagonist, antiemetic agent for nausea and vomiting, and in vitro anticancer agent for melanoma cells. This article offers a unique, in-depth analysis of its molecular mechanisms and translational potential in cancer and antiviral research.
Erastin: Precision Ferroptosis Inducer for Advanced Cance...
2026-02-26
Erastin stands as the benchmark ferroptosis inducer, empowering researchers to unravel iron-dependent, non-apoptotic cell death in RAS/BRAF-mutant cancers. With robust selectivity and validated protocols, Erastin from APExBIO accelerates breakthroughs in cancer biology, oxidative stress assays, and next-generation therapeutic strategies.
AZD2461: Novel PARP Inhibitor Transforming Breast Cancer ...
2026-02-26
AZD2461, a potent poly (ADP-ribose) polymerase inhibitor from APExBIO, empowers breast cancer researchers to overcome Pgp-mediated drug resistance and achieve robust, reproducible cell cycle arrest at the G2 phase. This guide provides actionable workflows, comparative insights, and troubleshooting strategies to maximize the impact of AZD2461 in both in vitro and in vivo settings.
Prochlorperazine: Dopamine D2 Antagonist for Antiemetic a...
2026-02-25
Prochlorperazine is a phenothiazine derivative and dopamine D2 receptor antagonist used as an antiemetic agent for nausea and vomiting, and as an in vitro inhibitor of melanoma cell proliferation and migration. Its mechanism also includes antiviral activity via clathrin-mediated endocytosis inhibition, making it a versatile research tool.
AZD2461: Redefining PARP Inhibition for Translational Bre...
2026-02-25
Explore the mechanistic, experimental, and translational significance of AZD2461—a next-generation PARP inhibitor—focusing on its unique ability to overcome Pgp-mediated resistance, modulate DNA repair, and extend relapse-free survival in breast cancer models. This thought-leadership article integrates evidence-based insights, strategic guidance, and visionary perspectives for translational researchers aiming to maximize the clinical impact of poly (ADP-ribose) polymerase inhibitors.
AZD2461 (SKU A4164): Scenario-Driven Solutions for Robust...
2026-02-24
This article provides a scenario-based, evidence-driven guide for leveraging AZD2461 (SKU A4164) in cell viability, proliferation, and cytotoxicity assays. It addresses practical laboratory challenges—ranging from optimizing assay parameters to selecting a reliable PARP inhibitor—equipping researchers with actionable insights supported by quantitative data, peer-reviewed literature, and direct product resources.
17-AAG (Tanespimycin): Real-World Solutions for Reliable ...
2026-02-24
This article provides a scenario-driven, evidence-based guide for biomedical researchers evaluating 17-AAG (Tanespimycin), SKU A4054, as an HSP90 inhibitor in cell viability and cytotoxicity assays. Drawing on quantitative data and best practices, it addresses common laboratory challenges and illustrates how 17-AAG (Tanespimycin) from APExBIO delivers reproducible, high-quality results for diverse cancer models.
7814 records 30/521 page Previous Next First page 上5页 2627282930 下5页 Last page